This article summarizes the recent history of respiratory research in New Zealand which was triggered by an epidemic of asthma mortality in the 1980s and which led to the rapid emergence of quality research groups. This unique event led to major initiatives to improve the standards of care for people with asthma in New Zealand. Perspectives on other lung health issues including tobacco control, the COPD epidemic and the emergence of bronchiectasis as a serious respiratory disease are also provided. Chronic Respiratory Disease 2006; 3: 167-169
The sudden revelation in 1981 1 that young people were dying unexpectedly from asthma, confirmed the following year as a national phenomenon 2 surprised and alarmed senior clinicians, politicians and then junior medical staff, such as ourselves. The recognition of this problem was a watershed for asthma research in New Zealand and trying to unravel the reasons for it, became something of a cause célèbre. For eager researchers looking for something to do it was a fascinating opportunity, that it should have happened at all was a considerable tragedy. The increased mortality immediately suggested problems with asthma management, and concern for appropriate and evidence based management practices have been a major research focus in New Zealand, ever since.
There was considerable international interest in this unexpected New Zealand mortality problem, especially as it had obvious echoes of the asthma mortality epidemic of the 1960s that had involved a number of countries. 3, 4 Interestingly, the first reports of increased mortality from isoprenaline in 1964 also came from the Antipodes. 5 An initial confidential enquiry confirmed the increased mortality and the underestimate of asthma severity by doctors and patients and its consequent undertreatment, but was unable to pinpoint the cause. Painstaking and at times controversial research showed that the overuse of one potent short acting beta-agonists had caused the epidemic 6 and later studies suggested that the under use of inhaled corticosteroids was a further contributing factor. The epidemic began in 1976, within a year of the introduction of fenoterol and ended within three months of its effective withdrawal from the market in 1989. 7 Like many an epidemic or national health problem there were important lessons to be learned. One of the first was the importance of looking at mortality statistics. The rising trend in asthma mortality from 1976 had been faithfully recorded each year but no one had registered the fact. It was only when a member of the Auckland asthma society, alarmed by the number of members and friends dying from asthma, suggested that asthma mortality might warrant some investigation that a small cluster of unexpected deaths were reported. 1 The method of further enquiry was based on the previous British Thoracic Society enquiries of mortality in the 1960s. This study provided much valuable information 8 but could never confirm a cause. In the same way that a randomized controlled trial must have controls, a case series becomes a much more powerful tool when controls are matched in the form of a case control study. The third lesson comes from an early study that showed that New Zealand had experienced a large increase in the sales of beta agonists, two to three years after asthma mortality had started to increase. 9 The obvious interpretation was that there had been some undetected change in the New Zealand environment that had made asthma more severe and the perfectly appropriate response was the prescription of more bronchodilators. The association between increasing sales of bronchodilators and increasing mortality only became apparent when individual beta agonists were considered separately.
The widely held assumption that all beta agonists were created equal was clearly incorrect.
In the years that followed the end of the epidemic, and in the light of it, New Zealand was at the forefront of asthma management research and pioneered the widespread introduction of self-management plans and free peak flow meters. Further research exploring the potential adverse effects of short acting beta agonists followed and many colleagues from around New Zealand and Australia made major contributions to the body of research evidence on this topic. Despite this further effort the reasons for the deleterious effects of fenoterol remain unknown. These New Zealand experiences led to caution and delay in the introduction of long acting betaagonists, and the mortality epidemic experiences continue to shape research today. For example, the recent meta analysis showing that commonly prescribed doses of inhaled corticosteroids are well above the steep portion of the dose response curve 10 and the pioneering studies on the diagnostic and management potential of exhaled nitric oxide are both studies designed to improve asthma management. 11 Throughout the late 1980s and 1990s many New Zealand clinicians and scientists became interested in asthma, especially in epidemiology, clinical trials and the role of self management. Major asthma research groups flourished in the main centres and gradually information was systematically gathered on the prevalence of asthma in adults and children. The European Respiratory Health Survey was undertaken in Wellington, Christchurch and the Hawkes Bay, demonstrating that asthma prevalence was amongst the highest in the world -around 15% in adults living in these metropolitan areas. 12 Soon thereafter, Phase I of the International Study of Asthma and Allergies in childhood, ISAAC was launched. 13 That research also showed that wheezing in children is very common with up to 25% of children affected in New Zealand and that there is wide variation around the world. A follow-up study involving many centres will be published shortly and is a great tribute to many researchers both in New Zealand and around the globe.
Based on similar studies, up to 10 years apart, it became clear that the prevalence of reported asthma symptoms had been rising steadily through the 1970s and 1980s. 14 Evidence is now accumulating that asthma prevalence, at least in some economically developed countries, may have reached a plateau, 15 though clearly not in all. 16 The reasons for this increase in asthma symptom prevalence remain a mystery. A large proportion is likely related to changes in diagnostic fashion with the shift in the 1970s to label all wheezing as asthma. 17 The early life wheezing phenotypes are now beginning to be unravelled and it is clear that many factors contribute to wheezy syndromes. 18 Nevertheless, there is evidence that atopic sensitization has increased 19 which would obviously increase the prevalence of atopic asthma. Despite the debate about the relationships between asthma and allergy, 20 in New Zealand most of the prevalence and morbidity is related to allergic asthma. 21 Consequently there has been intense interest in factors that might increase the prevalence of atopy, most notably those associated with reduced microbial and infectious disease exposure -the hygiene hypothesis. 22 The contributions of genetic and environmental factors and interactions between them are now being widely researched world wide, including a major New Zealand cohort study whose participants are now being studied at the age of six years.
Tobacco control continues to be at the forefront of public health policy. The New Zealand Government, and especially our Prime Minister, Rt Hon Helen Clarke, has led the way internationally in many aspects of tobacco control -the pen being considerably mightier than the scalpel. The Labour led Coalition Government, with the strong support of the Green Party has enacted far reaching legislation on tobacco including wide ranging restrictions on advertising and sponsorship, health warnings on packs and at point of sale and major restrictions on smoking in public places and buildings. Despite this excellent track record, smoking rates in New Zealand have not fallen as fast as might have been expected and have barely reduced since 1990. Smoking among young people and amongst young Maori in particular remain disappointingly high. 23 Bold new approaches to tackling this problem are urgently required.
New Zealand, like many other countries, is experiencing an epidemic of smoking related lung diseases. Lung cancer rates among Maori are the highest in the world and the prevalence of COPD is rising steadily in line with worldwide trends. This serious health problem has not been met with innovative health policy or action. When New Zealand determined its overarching health strategy in the late 1990s, for inexplicable reasons, respiratory disease did not feature highly, except through support for tobacco control and extra resources for smoking cessation, though as elsewhere these remain pitifully small in comparison to the size of the health burden, and to the size of the revenue gathered from the sale of tobacco. As a result the health boards in New Zealand did not receive much in the way of guidance or funding support for respiratory initiatives. In particular the increasing burden of COPD has created pressure on health services especially in the secondary care sector with rising admission rates, medication requirements and support needs exceeding resource allocation in many areas. The cost of COPD to the New Zealand economy has been estimated at NZ$200 M annually. Interestingly, the advocacy for further resources and prioritisation has been left to patients and consumer groups such as the Asthma and Respiratory Foundation of New Zealand. This has largely failed.
Attention in New Zealand is now turning to focus on the respiratory health of young people in a broad based initiative based on healthier homes, minimization of social deprivation, and access to good quality primary care services. Various ministries are working with health professionals in this area to ensure that risk factors for lung disease are reduced, especially smoking in the home, and that respiratory symptoms are noticed and investigated. One disorder that presents a significant challenge is the prevalence of bronchiectasis in young people, especially amongst Pacific Peoples and Maori. While the origins of this are not fully elucidated, it is clear that access to health services may allow the problem to go unrecognized.
Thus New Zealand continues to have significant respiratory health challenges. Others exist, such as the rising rates of TB and a relative lack of funding for modern pharmaceuticals and respiratory research. Importantly, advocacy continues through lay and professional groups who struggle to ensure that the needs of patients are not overlooked.
